ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Sales of Investments

Cash received from selling or redeeming investments.

ImmunityBio, Inc.NASDAQ: IBRX

Sales of Investments · Q3 FY2026 · quarter ended Sep 2026

Sales of investments outflow grows to $104.4M

Q3 FY2026 sales of investments was $104.4M, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $374.39M.

Context

  • Sales of investments amounted to 84.6% of revenue in FY2025, down 841.9 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly sales of investments holds near $104.4M or moves back toward the trailing-twelve-month quarterly average of $93.6M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$104.4M+73.2% QoQ
Last fiscal yearDec 2025
$95.82M-29.9% YoY
LTMSep 2026
$374.39M+1501.0% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-29.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
95.82M USD
Year-over-year change
-29.9%

Sales of Investments vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1501.0% is the highest of 11, against a peer median of -35.1%.
  • Sales of investments amounts to 205.1% of revenue for IBRX, versus a peer median of 145.4%.
IBRX Competitors
Sales of Investments for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€10.31B EUR-19.6%+189.9%389.9%
MRNAModerna, Inc.LTM Sep 2026$5.45B USD-34.0%+5.7%215.6%
VIRVir Biotechnology, Inc.LTM Mar 2026$1.07B USD-26.1%+50.6%1633.7%
LEGNLegend Biotech CorporationLTM Sep 2026$1.02B USD-79.1%+105.5%75.2%
IBRXImmunityBio, Inc.LTM Sep 2026$374.39M USD+1501.0%—205.1%
NKTXNkarta, Inc.LTM Mar 2026$335.26M USD+13.7%+11.1%—
IMTXImmatics N.V.LTM Mar 2026€282.39M EUR-50.0%+246.5%757.1%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$262M USD-41.3%-8.5%69.1%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$249.82M USD-36.1%-13.3%—
IMCRImmunocore Holdings plcLTM Mar 2026$13.99M USD+39.9%—3.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$7.89M USD-74.5%-55.9%34.1%
Peer median (excluding IBRX) —-35.1%+11.1%145.4%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(346.79M)(416.57M)(583.85M)(413.65M)(351.47M)
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
Deferred Income Tax00000
Stock-Based Compensation57.18M40.18M49.16M34.43M36.81M
Change in Working Capital(15.4M)(16M)3.83M(19.42M)(54.33M)
Accounts Receivables000(2.36M)(40.21M)
Inventory000(8.27M)(6.33M)
Accounts Payables00(6.48M)(3.17M)(190K)
Other Working Capital(15.4M)(16M)10.3M(5.62M)(7.6M)
Other Non-Cash Items16.35M36.62M145.44M(10.16M)48.53M
Operating Cash Flow(274.42M)(337.51M)(366.76M)(391.24M)(304.94M)
Capital Expenditures(33.56M)(78.16M)(30.58M)(6.89M)(3.85M)
Acquisitions (Net)000(1M)0
Purchases of Investments00(10.36M)(140.22M)(241.37M)
Sales of Investments0010.47M136.61M95.82M
Other Investing Activities(51.32M)105.46M0(747K)0
Investing Cash Flow(84.89M)27.3M(30.47M)(12.25M)(149.8M)
Debt Repayment338.5M174.07M451.39M96.89M1.72M
Common Stock Issued00110.4M111.36M400.78M
Common Stock Repurchased(4.06M)(616K)000
Dividends Paid00000
Other Financing Activities171.01M60.16M(3.44M)73.38M(2.27M)
Financing Cash Flow505.44M233.61M558.34M281.63M400.24M
Effect of Forex Changes48K284K(292K)(23K)15K
Net Change in Cash146.19M(76.32M)160.82M(121.88M)(54.48M)
Free Cash Flow(307.98M)(415.67M)(397.34M)(398.12M)(308.78M)

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.